Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

West Virginia University football head coach Rich Rodriguez gave his latest assessment of his Mountaineer football team on ...

The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S. The drug was ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill brensocatib, which will be sold under the brand ...

Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

A simple 3-step system helped identify breakout trades like DAVE (87%), MP (45%), and OUST (56%), before they moved. Join us ...

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...